WO2015128789A1 - Inhaler - Google Patents
Inhaler Download PDFInfo
- Publication number
- WO2015128789A1 WO2015128789A1 PCT/IB2015/051350 IB2015051350W WO2015128789A1 WO 2015128789 A1 WO2015128789 A1 WO 2015128789A1 IB 2015051350 W IB2015051350 W IB 2015051350W WO 2015128789 A1 WO2015128789 A1 WO 2015128789A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhaler device
- base plate
- amino
- mouthpiece
- inhaler
- Prior art date
Links
- 239000003814 drug Substances 0.000 claims abstract description 40
- 239000002775 capsule Substances 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 6
- 238000007689 inspection Methods 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 43
- -1 KUL-1248 Chemical compound 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- FIMXSEMBHGTNKT-UHFFFAOYSA-N Scopine Natural products CN1C2CC(O)CC1C1C2O1 FIMXSEMBHGTNKT-UHFFFAOYSA-N 0.000 description 11
- FIMXSEMBHGTNKT-RZVDLVGDSA-N scopine Chemical compound C([C@@H]1N2C)[C@H](O)C[C@@H]2[C@@H]2[C@H]1O2 FIMXSEMBHGTNKT-RZVDLVGDSA-N 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 10
- 239000002253 acid Substances 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- ODELFXJUOVNEFZ-UHFFFAOYSA-N 2,2-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C(O)=O)(C)C1=CC=CC=C1 ODELFXJUOVNEFZ-UHFFFAOYSA-N 0.000 description 3
- GXAMYUGOODKVRM-UHFFFAOYSA-M 9-hydroxyfluorene-9-carboxylate Chemical compound C1=CC=C2C(O)(C([O-])=O)C3=CC=CC=C3C2=C1 GXAMYUGOODKVRM-UHFFFAOYSA-M 0.000 description 3
- DTZDZCNXNYMMOW-UHFFFAOYSA-N 9-hydroxyxanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)(O)C3=CC=CC=C3OC2=C1 DTZDZCNXNYMMOW-UHFFFAOYSA-N 0.000 description 3
- PUPWRKQSVGUBQS-UHFFFAOYSA-N 9-methylfluorene-9-carboxylic acid Chemical compound C1=CC=C2C(C)(C(O)=O)C3=CC=CC=C3C2=C1 PUPWRKQSVGUBQS-UHFFFAOYSA-N 0.000 description 3
- CBNOKZSYCBHRAD-UHFFFAOYSA-N 9-methylxanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C)(C(O)=O)C3=CC=CC=C3OC2=C1 CBNOKZSYCBHRAD-UHFFFAOYSA-N 0.000 description 3
- ZMXHONJJTQSZKY-UHFFFAOYSA-N 2,2-bis(3,4-difluorophenyl)-2-hydroxyacetic acid Chemical compound C=1C=C(F)C(F)=CC=1C(O)(C(=O)O)C1=CC=C(F)C(F)=C1 ZMXHONJJTQSZKY-UHFFFAOYSA-N 0.000 description 2
- RCORMCWYMRPHPO-UHFFFAOYSA-N 2,2-bis(3-fluorophenyl)-2-hydroxyacetic acid Chemical compound C=1C=CC(F)=CC=1C(O)(C(=O)O)C1=CC=CC(F)=C1 RCORMCWYMRPHPO-UHFFFAOYSA-N 0.000 description 2
- YKZXWNCXGVYCKF-UHFFFAOYSA-N 2,2-bis(4-fluorophenyl)-2-hydroxyacetic acid Chemical compound C=1C=C(F)C=CC=1C(O)(C(=O)O)C1=CC=C(F)C=C1 YKZXWNCXGVYCKF-UHFFFAOYSA-N 0.000 description 2
- MAGCRYYXZYUDSY-UHFFFAOYSA-N 2-fluoro-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(F)(C(=O)O)C1=CC=CC=C1 MAGCRYYXZYUDSY-UHFFFAOYSA-N 0.000 description 2
- PYUGFOWNYMLROI-KPKJPENVSA-N 8-[(e)-2-[4-[4-(4-fluorophenyl)butoxy]phenyl]ethenyl]-2-(2h-tetrazol-5-yl)chromen-4-one Chemical compound C1=CC(F)=CC=C1CCCCOC(C=C1)=CC=C1\C=C\C1=CC=CC2=C1OC(C=1NN=NN=1)=CC2=O PYUGFOWNYMLROI-KPKJPENVSA-N 0.000 description 2
- BHEFSGMUMYBJRZ-UHFFFAOYSA-N 9-fluorofluorene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)(F)C3=CC=CC=C3C2=C1 BHEFSGMUMYBJRZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 2
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 2
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- KYFWUBJMTHVBIF-QFIPXVFZSA-N dsstox_cid_27248 Chemical compound N([C@@H]1N=C(C=2C=3N(C1=O)CCC=3C=C(C=2)C)C=1C=CC=CC=1)C(=O)C1=CC=NC=C1 KYFWUBJMTHVBIF-QFIPXVFZSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- QAIOVDNCIZSSSF-RFAJLIJZSA-N etiprednol dicloacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](OC(=O)C(Cl)Cl)(C(=O)OCC)[C@@]1(C)C[C@@H]2O QAIOVDNCIZSSSF-RFAJLIJZSA-N 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000005635 hydromethanesulphonate group Chemical group 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- YTKFKKLZSIVJMX-ZDUSSCGKSA-N (6s)-4-[2-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxyethyl]-6-methylmorpholin-2-one Chemical compound C=12C=C(OCCN3CC(=O)O[C@@H](C)C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 YTKFKKLZSIVJMX-ZDUSSCGKSA-N 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- LITNEAPWQHVPOK-FFSVYQOJSA-N 2(1h)-pyrimidinone, 5-[3-[(1s,2s,4r)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl]tetrahydro- Chemical compound C1=C(O[C@@H]2[C@H]3CC[C@H](C3)C2)C(OC)=CC=C1C1CNC(=O)NC1 LITNEAPWQHVPOK-FFSVYQOJSA-N 0.000 description 1
- PDYTYRKWKWQHNC-CQSZACIVSA-N 2-[(4s)-4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-ylidene]butanoic acid Chemical compound C1NC(=C(C(O)=O)CC)C[C@H]1C1=CC=C(OC)C(OC2CCCC2)=C1 PDYTYRKWKWQHNC-CQSZACIVSA-N 0.000 description 1
- PSILZZNMGXTOOP-UHFFFAOYSA-N 2-[2-[[2-(4-tert-butyl-1,3-thiazol-2-yl)-1-benzofuran-5-yl]oxymethyl]phenyl]acetic acid Chemical compound CC(C)(C)C1=CSC(C=2OC3=CC=C(OCC=4C(=CC=CC=4)CC(O)=O)C=C3C=2)=N1 PSILZZNMGXTOOP-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 description 1
- KLPQJJKXRIDASJ-UHFFFAOYSA-N 3-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]-N-ethyl-8-propan-2-yl-7H-purin-6-imine Chemical compound CCN=C1C2=C(N=C(N2)C(C)C)N(C=N1)CC3=CC(=C(C=C3)OC)OC4CCCC4 KLPQJJKXRIDASJ-UHFFFAOYSA-N 0.000 description 1
- GBTODAKMABNGIJ-UHFFFAOYSA-N 3-[4-[6-[[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]hexoxy]butyl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(CCCCOCCCCCCNCC(O)C=2C=C(CO)C(O)=CC=2)=C1 GBTODAKMABNGIJ-UHFFFAOYSA-N 0.000 description 1
- ULMFXAMQUGLVGA-LJQANCHMSA-N 3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-n-[(2r)-4,4,4-trifluoro-2-methylbutyl]indole-5-carboxamide Chemical compound C=1C=C(CC=2C3=CC(=CC=C3N(C)C=2)C(=O)NC[C@H](C)CC(F)(F)F)C(OC)=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C ULMFXAMQUGLVGA-LJQANCHMSA-N 0.000 description 1
- LIXBJWRFCNRAPA-NSHDSACASA-N 4-[(1r)-2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C=C1Cl LIXBJWRFCNRAPA-NSHDSACASA-N 0.000 description 1
- UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 description 1
- LIXBJWRFCNRAPA-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C=C1Cl LIXBJWRFCNRAPA-UHFFFAOYSA-N 0.000 description 1
- ALPHJXMCUQHURK-SFHVURJKSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-[[(2s)-oxolan-2-yl]methoxy]quinazolin-6-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C1C(=O)OC(C)(C)CN1CCOC(C(=CC1=NC=N2)OC[C@H]3OCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 ALPHJXMCUQHURK-SFHVURJKSA-N 0.000 description 1
- CFBUZOUXXHZCFB-UHFFFAOYSA-N 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-cyclohexanecarboxylic acid Chemical compound COC1=CC=C(C2(CCC(CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- QZZUEBNBZAPZLX-UHFFFAOYSA-N 5-[2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2C(O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-UHFFFAOYSA-N 0.000 description 1
- XMOAAORIXBPOCZ-UHFFFAOYSA-N 9-(difluoromethyl)xanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)(C(F)F)C3=CC=CC=C3OC2=C1 XMOAAORIXBPOCZ-UHFFFAOYSA-N 0.000 description 1
- ZRDOWGBNGIHJTG-UHFFFAOYSA-N 9-(hydroxymethyl)xanthene-9-carboxylic acid Chemical compound C1=CC=C2C(CO)(C(O)=O)C3=CC=CC=C3OC2=C1 ZRDOWGBNGIHJTG-UHFFFAOYSA-N 0.000 description 1
- QPVQJRWUNUHSJL-UHFFFAOYSA-N 9-ethylxanthene-9-carboxylic acid Chemical compound C1=CC=C2C(CC)(C(O)=O)C3=CC=CC=C3OC2=C1 QPVQJRWUNUHSJL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- QGBIFMJAQARMNQ-QISPFCDLSA-N C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O QGBIFMJAQARMNQ-QISPFCDLSA-N 0.000 description 1
- PEHNBYTXRHCHKF-IYBDPMFKSA-N C=12C=C(O[C@@H]3CC[C@@H](CC3)N(C)S(C)(=O)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 Chemical compound C=12C=C(O[C@@H]3CC[C@@H](CC3)N(C)S(C)(=O)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 PEHNBYTXRHCHKF-IYBDPMFKSA-N 0.000 description 1
- JEFIMDCWCOALTI-WGSAOQKQSA-N C=12C=C(O[C@@H]3CC[C@H](CC3)N(C)C(=O)N3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 Chemical compound C=12C=C(O[C@@H]3CC[C@H](CC3)N(C)C(=O)N3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 JEFIMDCWCOALTI-WGSAOQKQSA-N 0.000 description 1
- FOMMTKFJEREKRS-WKILWMFISA-N C=12C=C(O[C@@H]3CC[C@H](CC3)N(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 Chemical compound C=12C=C(O[C@@H]3CC[C@H](CC3)N(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 FOMMTKFJEREKRS-WKILWMFISA-N 0.000 description 1
- PEHNBYTXRHCHKF-WKILWMFISA-N C=12C=C(O[C@@H]3CC[C@H](CC3)N(C)S(C)(=O)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 Chemical compound C=12C=C(O[C@@H]3CC[C@H](CC3)N(C)S(C)(=O)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 PEHNBYTXRHCHKF-WKILWMFISA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 229920004943 Delrin® Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- RUOGJYKOQBFJIG-UHFFFAOYSA-N SCH-351591 Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)NC1=C(Cl)C=[N+]([O-])C=C1Cl RUOGJYKOQBFJIG-UHFFFAOYSA-N 0.000 description 1
- VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical class C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 description 1
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 description 1
- CDKNUFNIFGPFSF-AYVLZSQQSA-N [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-propanoylsulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O CDKNUFNIFGPFSF-AYVLZSQQSA-N 0.000 description 1
- WKHOPHIMYDJVSA-UHFFFAOYSA-N [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate Chemical compound CC(C)C(=O)OC1=CC(OC(=O)C(C)C)=CC(C(O)CNC(C)(C)C)=C1 WKHOPHIMYDJVSA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- GVTLDPJNRVMCAL-UHFFFAOYSA-N arofylline Chemical compound C1=2N=CNC=2C(=O)N(CCC)C(=O)N1C1=CC=C(Cl)C=C1 GVTLDPJNRVMCAL-UHFFFAOYSA-N 0.000 description 1
- 229950006944 atizoram Drugs 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- JBRBWHCVRGURBA-UHFFFAOYSA-N broxaterol Chemical compound CC(C)(C)NCC(O)C1=CC(Br)=NO1 JBRBWHCVRGURBA-UHFFFAOYSA-N 0.000 description 1
- 229950008847 broxaterol Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 229960001386 carbuterol Drugs 0.000 description 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- HSDBULQDKRYING-UHFFFAOYSA-N cyclopropyltropine benzilate Chemical compound C1C(C2C3C2)N(C)C3CC1OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 HSDBULQDKRYING-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229950006990 etiprednol dicloacetate Drugs 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229950008319 flutropium bromide Drugs 0.000 description 1
- FNUZASGZEHGWQM-RJRMRWARSA-M flutropium bromide Chemical compound C[N@+](CCF)([C@H](CC1)C2)[C@@H]1C[C@H]2OC(C(C1=CC=CC=C1)(C1=CC=CC=C1)O)=O.[Br-] FNUZASGZEHGWQM-RJRMRWARSA-M 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960000708 hexoprenaline Drugs 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- TWTMQRXNAZGSCE-UHFFFAOYSA-N hydron;[6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;chloride Chemical compound Cl.C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 TWTMQRXNAZGSCE-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229950002451 ibuterol Drugs 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229950001737 meluadrine Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- MEQKIBIRCVJSRK-UHFFFAOYSA-N methyl 2,2-bis(4-fluorophenyl)-2-hydroxyacetate Chemical compound C=1C=C(F)C=CC=1C(O)(C(=O)OC)C1=CC=C(F)C=C1 MEQKIBIRCVJSRK-UHFFFAOYSA-N 0.000 description 1
- FXXQDYPNDZFBMV-UHFFFAOYSA-N methyl 5-cyano-5-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxocyclohexane-1-carboxylate Chemical compound C1CC(=O)C(C(=O)OC)CC1(C#N)C1=CC=C(OC(F)F)C(OCC2CC2)=C1 FXXQDYPNDZFBMV-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- RZYANQUZIRWZBS-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-piperidin-3-yloxyquinazolin-4-amine Chemical compound C=12C=C(OC3CNCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 RZYANQUZIRWZBS-UHFFFAOYSA-N 0.000 description 1
- YOBLCEDHQQYBEJ-UHFFFAOYSA-N n-(3-ethynylphenyl)-7-methoxy-6-(1-methylpiperidin-4-yl)oxyquinazolin-4-amine Chemical compound C=12C=C(OC3CCN(C)CC3)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 YOBLCEDHQQYBEJ-UHFFFAOYSA-N 0.000 description 1
- QROHAWMNESUZHZ-UHFFFAOYSA-N n-(3-ethynylphenyl)-7-methoxy-6-(oxan-4-yloxy)quinazolin-4-amine Chemical compound C=12C=C(OC3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 QROHAWMNESUZHZ-UHFFFAOYSA-N 0.000 description 1
- PQTDSJWQNYBZMA-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OCC1CC1)=C2NC(=O)C=CCN1CCOCC1 PQTDSJWQNYBZMA-UHFFFAOYSA-N 0.000 description 1
- ADOYXBQVLRRQGX-OAQYLSRUSA-N n-[7-cyclopentyloxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C1=CC=2NC(=O)C=CCN3CCOCC3)=NC=NC1=CC=2OC1CCCC1 ADOYXBQVLRRQGX-OAQYLSRUSA-N 0.000 description 1
- 229960001609 oxitropium bromide Drugs 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 229960001634 ritodrine Drugs 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229950001879 salmefamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229950010302 tiaramide Drugs 0.000 description 1
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960001530 trospium chloride Drugs 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0025—Mouthpieces therefor with caps
- A61M15/0026—Hinged caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
- A61M15/0041—Details of the piercing or cutting means with movable piercing or cutting means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/586—Ergonomic details therefor, e.g. specific ergonomics for left or right-handed users
Definitions
- the present invention relates to an inhalation device for inhalation of powdered pharmaceutical compositions contained in capsules which are inserted in a medicament holder of the inhalation device.
- the powdered inhalation devices are used for inhaling either single or multi-dose of powdered medicament from capsules.
- the devices are configured to have medicament holders which hold the capsules containing the powdered medicament.
- a piercing mechanism provided with the device pierces the capsule and enables the medicament to get dispersed into the air sucked by the user during the process of inhalation.
- the emptied capsule remains in the device which is then discarded prior to the next use of the device.
- US 3,807,400 discloses some improvements in the inhaling devices with whirling chamber, devices that may be considered in their essential operation per se known and are intended to disperse the contents of a capsule filled with a powder medicinal composition.
- the device according to the invention provides a mouth piece that is a telescopic structure and two piercing devices that are placed into a rotatable member according to a diametral opposed position and are actuated by the member, the telescoping structure when extended forming the whirling chamber, the mantel of the latter mentioned member being formed with a cam able to give a number of piercing operations to both piercing devices.
- US 8,006,695 describes an inhaler device for inhalation of a medicament from a pierceable capsule comprises a housing for receiving a medicament capsule; closure means for closing the housing, said closure means being moveable relative to the housing; piercing means suitable for piercing a medicament capsule; wherein movement of the closure means relative to the housing causes movement of the piercing means.
- the invention also provides a holder for a medicament capsule which holder comprises a chamber suitable for receiving a medicament capsule; and means for generating turbulence in a fluid flow through the chamber such that, in use, the turbulent fluid flow causes vibration of a capsule received by the chamber so as to assist in releasing medicament contained within the capsule.
- US 7,694,676 describes an inhaler for inhaling powdered pharmaceutical compositions from capsules includes: a lower part; a plate which can be latched to the lower part and with which the lower part can be closed off; a capsule holder for receiving the capsules, this holder being adapted to be lowered into the lower part; a mouthpiece latchable to the plate; a lid which covers the mouthpiece in a closed position and latches it by means of a closure element, the lower part, the plate, the mouthpiece and the lid being hinged together by means of a single joint.
- US 8,022,082 discloses an inhaler comprising: a housing containing two windows, a deck in which there are air inlet ports and which is provided with a screen secured by a screen housing, an inhalation chamber connected to the deck on which there is a push button provided with two sharpened pins and movable counter to a spring, a mouthpiece which is connected to the housing, the deck, and a cover via a spindle to enable it to be flipped open or shut, and three holes with diameters below 1 mm in the central region around the capsule chamber and underneath the screen housing and screen.
- US 7,252,087 discloses an inhaler utilizing a multi-functional actuating member.
- Multifunctional actuating member as disclosed in US '087 in a first functional position allows a closure element to be disengaged from a lower part of the housing, and in a second functional position allows a mouthpiece to be pivoted away from the lower part of the housing.
- US 7,284,553 discloses a powder inhaler operating on the Bernoulli principle. It discloses an inhaler with a capsule chamber including raised elements on either the inner surface of the capsule chamber or on the outer surface of the capsule.
- the invention is thus concerned with improved inhaling devices with two hinge system intended to disperse the contents of the powdered pharmaceutical composition.
- patient opens the lid, then the mouth piece and inserts the capsule containing powdered pharmaceutical composition.
- Patient then presses the actuating member that leads to piercing of the capsule containing powdered pharmaceutical composition.
- the piercing elements attached to the actuating member pierce the capsule from one side allowing the powdered pharmaceutical composition contained in the capsule to come out when the patient inhales from the mouthpiece.
- the 'two hinge' design in the inhaler of present invention employs two separate hinges.
- One hinge is for the lid and the mouth piece and second is for the base plate.
- the patient is required to open the base plate only as and when required.
- Use of second and distinct hinge prevents the accidental opening of the base plate, thereby avoiding the contamination of the medicament.
- the non-protruding actuating member makes handling and storing of the device very convenient.
- the shape of the inhaler which is round across the top and on one side is configured at an angle in such a way that patient is able to have an appropriate grip on the device and finds it very convenient to actuate the device without losing control over the holding of the device Ob jects of invention
- An object of the present invention is to overcome the drawbacks of the prior art.
- Another object of the present invention is to provide an inhaler device with two hinge systems (6, 8).
- Yet another object of the present invention is to provide an inhaler device with two hinge systems, wherein the mouthpiece (3) and the lid (1) is joined to a single hinge (8).
- Yet another object of the present invention is to provide an inhaler device with two hinge systems, wherein the base plate (4) is hinged separately from the mouthpiece and lid to hinge (6).
- Yet another object of the present invention is to provide an inhaler utilizing base plate (4) devoid of any holes.
- Yet another object of the present invention is to provide an inhaler wherein the gripping aid (9) is disposed distal to the actuating member (5).
- an inhaler device comprising: a housing (2), a base plate (4) covering the housing (2), a medicament holder (10) integrated with the base plate (4), a mouthpiece (3) sitting over the base plate (4), a lid (1) which covers the mouthpiece (3), at least one piercing element (11), an actuating member
- the inhaler device is a two hinge system (6,8) wherein the base plate (4) is joined to hinge (6); the mouthpiece (3) and the lid (1) are joined to the hinge (8).
- FIG. 1 illustrates the essential components of the inhaler in accordance with the present invention wherein the housing (2) which accommodates the base plate (4) and is covered by the latter, the mouthpiece (3) with gripping aid (9).
- the base plate (4) is joined to the hinge
- the gripping aid (9) is disposed distal to the actuating member (5).
- Figure 2 illustrates the Top view of the medicament holder (10) mounted on the underside of the base plate (4).
- Figure 3 illustrates the closed view of the mouthpiece (3) sitting over the base plate (4) that is integrated with the medicament holder (10).
- the two hinges (6, 8) are distinctly marked.
- Figure 4 illustrates the radial partial sectional view of the inhaler depicting the lid (1), mouthpiece (3), piercing elements (11), actuating member (5), spring (12), medicament holder (10), inspection windows (7), and the mouthpiece and lid attached to hinge (8).
- Figure 5 illustrates the side perspective of the inhaler in a fully closed position.
- Figure 6 illustrates the top view of the inhaler base plate (4) devoid of any holes.
- Figure 7 illustrates the inhaler with distinct two hinge system (6, 8).
- Figure 8 illustrates the graph for square root of the pressure drop versus the flow rate in the present inhaler depicting relatively high resistance to air flow.
- an inhaler for inhaling powdered pharmaceutical compositions is provided from capsules which are inserted in a medication holder provided in the inhaler before use.
- the patient can press an actuating member which can be moved from a resting position, thereby cooperating with at least one piercing element which can enter into the medication holder.
- the capsule is pierced by the minimum of one piercing element and the pharmaceutical composition is released.
- the inhaler according to the present invention as shown in the figures 1, 2, 3 and 4 essentially comprises of a housing (2) which accommodates the base plate (4) and is covered by the latter, the mouthpiece (3) with gripping aid (9); the said base plate (4) is joined to the hinge (6) and the mouthpiece (3) and the lid (1) is hinged together distinctly from the base plate to hinge (8); The gripping aid (9) is disposed distal to the actuating member (5).Inspectional window (7) further allows to inspect the internal elements of the device.
- a medicament holder (10) is mounted on the underside of the base plate (4).
- One or more piercing elements (11) for piercing the capsules are attached from inside of the actuating member (5) and a spring (12) is also configured to link the actuating member; characterized in that the actuator when pressed from outside, the spring element (12) gets compressed and enables the piercing elements (11) to move linearly and pierce the capsule such that the medicament inside the capsule is released and the spring element retracts thereafter.
- a spring (12) is also configured to link the actuating member; characterized in that the actuator when pressed from outside, the spring element (12) gets compressed and enables the piercing elements (11) to move linearly and pierce the capsule such that the medicament inside the capsule is released and the spring element retracts thereafter.
- Lid (1) offers protection to the device components by preventing entry of dust or any other extraneous particles.
- Mouthpiece (3) is the component through which the patient inhales the powdered pharmaceutical composition.
- Base plate (4) ensures that the medicament holder (10) is held securely and always remains aligned to the mouth piece (3) for a smooth flow of the medicament.
- Actuating member (5) is responsible for locking & unlocking of the lid (1) and holds the piercing elements (11) in an appropriate position. When the actuating member (5) is moved forward, it ensures appropriate piercing of the capsule in such a way that the powdered pharmaceutical composition is available for inhalation by the patient.
- Hinge (6) is responsible for holding the base plate (4) in an appropriate position in such a way that the medicament holder (10) is always aligned to the mouth piece (3).
- Inspection window (7) provides a view of the medicament holder (10) and allows the patient to confirm the presence of capsule in the medicament holder (10).
- Hinge (8) is responsible for appropriate movement of the lid (1) and mouth piece (3).
- Gripping aid (9) on the mouth piece offers a grip for the patient to open the mouth piece so that the capsule containing the powdered pharmaceutical composition could be placed in the medicament holder (10).
- the inhaler is operated in the following manner. a) The lid (1) is opened by pressing the actuating member (5)
- the mouthpiece (3) is opened by pulling the gripping aid (9) located on both sides of the mouthpiece (3).
- the actuating member (5) is pressed to move the piercing element (11) to pierce the capsules.
- the device may be made from any suitable material.
- the device is made of plastic, for example ABS (acrylonitrile butadiene styrene), PC (polycarbonate), PA (polyacetal) or PS (polystyrene), or mixtures thereof, or of an antistatic material such as delrin or stainless steel
- the inhaler according to the invention allows the pharmaceutical composition to be delivered more reliably compared to the devices known from the prior art.
- the advantages of the present inhaler are as follows.
- the patient is required to open the base plate only as and when required.
- Use of second and distinct hinge prevents the accidental opening of the base plate, thereby avoiding the contamination of the medicament.
- the non-protruding actuating member makes handling of the device and storing of the device, very convenient.
- the shape of the inhaler which is round across the top and on one side, is configured at an angle in such a way that patient is able to have an appropriate grip on the device and finds it very convenient to actuate the device without losing control over the holding of the device
- An inhaler device with two hinge system utilizing a base plate devoid of any holes was measured to have a flow resistance of about 0.07 /L, mm ⁇ resulting in a flow rate of about 40 L min "1 with a pressure drop of about 4 kPa across the inhaler.
- the inhalation pressure drops of between 2 kpa and 6 kpa produced resultant flow rates of about between 25 and 55 liters per minute.
- the present invention relates to the use of an inhaler device as described above for the administration of powdered pharmaceutical composition that is suitable for the treatment of asthma or chronic obstructive pulmonary disease by inhalation.
- the pressure drop versus flow rate curve depends upon the construction of the inhaler.
- the inhaler in accordance with the present invention was tested to measure its resistance to flow which is an important characteristic of inhalers.
- the resistance of the inhaler is the slope of the linear portion of the curve.
- An exemplary graph can be seen in Fig 8 for an inhaler device in accordance with the present invention.
- the graph depicted in Fig 8 indicates relatively high resistance to air flow, the curve increasing rapidly with the flow rate.
- the inhaler according to the present invention may include design features provided by the recognition that different powdered drugs have different characteristics.
- the flow parameters of the inhaler should advantageously be adjusted for the specific drug being delivered. These adjustments can be made by adjusting the air flow.
- the air flow can be controlled by drilling additional air supply hole or by increasing and decreasing the size of the opening of the air supply hole.
- the powdered pharmaceutical composition contained within the capsule is a dry powder medicament.
- the term capsule is intended to be understood broadly and includes any suitable receptacle for powdered pharmaceutical compositions.
- the capsule may be formed from any suitable material, including gelatin, HPMC, or plastic.
- the invention provides pharmaceutical composition which includes powdered pharmaceuticals can be administered by inhalation.
- pharmaceutical compositions selected from among the anticholinergics, beta-2- agonists, steroids, PDE IV-inhibitors, LTD4-antagonists and EGFR-kinase inhibitors.
- Anticholinergics for use are preferably selected from among TIOTROPIUM bromide, oxitropium bromide, flutropium bromide, ipratropium bromide, glycopyrronium salts, trospium chloride, tolterodine, tropenol 2,2-diphenylpropionate methobromide, scopine 2,2- diphenylpropionate methobromide, scopine 2-fluoro-2,2-diphenylacetate methobromide, tropenol 2-fluoro-2,2-diphenylacetate methobromide, tropenol 3,3',4,4'-tetrafluorobenzilate methobromide, scopine 3,3',4,4'-tetrafluorobenzilate methobromide, tropenol 4,4'- difluorobenzilate methobromide, scopine 4,4'-difluorobenzilate methobromide, tropenol 3,3'- di
- Beta-2-agonists used are preferably selected from among albuterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, salmeterol, salmefamol, soterenot, sulphonterol, tiaramide, terbutaline, tolubuterol, CHF-1035, HOKU-81, KUL-1248, 3-(4- ⁇ 6- [2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyl- oxy ⁇ -butyl)- benzene
- the steroids used are preferably selected from among prednisolone, prednisone, butixocortpropionate, RPR-106541, flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, ST- 126, dexamethasone, (S)- fluoromethyl6.quadrature.,9.quadrature.-difluoro-17.quadrature.-[(2-f- uranylcarbonyl)oxy]- 1 l.quadrature.-hydroxy-16.quadrature.-methyl-3-oxo-and- rosta-l,4-diene-17.quadrature.- carbothionate, (S)-(2-oxo-tetrahydro-furan-3S-yl) 6.quadrature.,9.quadrature.-difluoro- 11.
- PDE IV inhibitors used are preferably selected from among enprofyllin, theophyllin, roflumilast, ariflo (cilomilast), CP-325,366, BY343, D-4396 (Sch-351591), AWD-12-281 (GW-842470), N-(3,5-dichloro-l-oxo-pyridin-4-yl)-4-difluoromethoxy-3- cyclopropylmethox- ybenzamide, NCS-613, pumafentine, (-)p-[(4aR*,10bS*)-9-ethoxy- 1,2,3, 4,4a, 10b-hexahydro-8-methoxy-2-methylbe- nzo[s][l,6]naphthyridin-6-yl]-N,N- diisopropylbenzamide, (R)-(+)-l-(4-bromobenzyl)-4-[(3-cyclopent
- LTD4-antagonists used are preferably selected from among montelukast, l-(((R)-(3-(2-(6,7- difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2-(2-hydroxy— 2- propyl)phenyl)thio)methylcyclopropane-acetic acid, l-(((l(R)-3(3-(2-(2,3- dichlorothieno[3,2-b]pyridin-5-yl)-(E)-ethenyl)phen- yl)-3-(2-(l -hydroxy- 1- methylethyl)phenyl)propyl)thio)methyl)cyclopropanace- tic acid, pranlukast, zafirlukast, [2- [[2-(4-tert-butyl-2-thiazolyl)-5-benzofuranyl]oxymethyl]phenyl]acetic acid, MCC-847 (ZD- 35
- EGFR-kinase inhibitors used are preferably selected from among cetuximab, trastuzumab, ABX-EGF, Mab ICR-62, 4-[(3-chloro-4-fluorophenyl)amino]-6- ⁇ [4-(morpholin-4-yl)-l-oxo- 2-buten- 1 - -yl] amino ⁇ -7-cyclopropylmethoxy-quinazoline, 4- [(R)-( 1 -phenyl-ethyl)amino] -6- ⁇ [4-(morpholin-4-yl)-l-oxo-2-buten-l-yl]— amino ⁇ -7-cyclopentyloxy-quinazoline, 4-[(3- chloro-4-fluoro-phenyl)amino]-6- ⁇ [4-((R)-6-methyl-2-oxo-morpholin-4- -yl)-l-oxo-2-buten-
- Examples of acid addition salts with pharmacologically acceptable acids which the compounds may be capable of forming include salts selected from among the hydrochloride, hydrobromide, hydroiodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate, preferably hydrochloride, hydrobromide, hydrosulphate, hydrophosphate, hydrofumarate and hydromethanesulphonate.
- the powdered pharmaceutical compositions may contain the above-mentioned active substances as well as the salts, esters thereof, or combinations of these active substances, salts and esters.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
An inhaler device comprising: a housing (2), a base plate (4) covering the housing (2), a medicament holder (10) integrated with the base plate (4), a mouthpiece (3) sitting over the base plate (4), a lid (1) which covers the mouthpiece (3), at least one piercing element (11), an actuating member (5), a spring (12), and is characterized in that the inhaler device is a two hinge system (6,8) wherein the base plate (4) is joined to hinge (6); the mouthpiece (3) and the lid (1) are joined to the hinge (8).
Description
INHALER
Field of the invention
The present invention relates to an inhalation device for inhalation of powdered pharmaceutical compositions contained in capsules which are inserted in a medicament holder of the inhalation device.
Background of the invention
The invent of inhalation devices paved a hassle free path for the treatment and management of respiratory disorders. Today dry powder inhalation devices play an important role in the field of targeted drug delivery to the affected airways of lungs. Dry powder inhalers (DPIs) have been available since 1967 and Aventis was first to develop DPI by name SPINHALER for the delivery of Sodium Cromoglycate. Since then, many improvements in the design and use of inhalation devices were observed.
In general the powdered inhalation devices are used for inhaling either single or multi-dose of powdered medicament from capsules. The devices are configured to have medicament holders which hold the capsules containing the powdered medicament. A piercing mechanism provided with the device pierces the capsule and enables the medicament to get dispersed into the air sucked by the user during the process of inhalation. The emptied capsule remains in the device which is then discarded prior to the next use of the device.
US 3,807,400 discloses some improvements in the inhaling devices with whirling chamber, devices that may be considered in their essential operation per se known and are intended to disperse the contents of a capsule filled with a powder medicinal composition. The device according to the invention provides a mouth piece that is a telescopic structure and two piercing devices that are placed into a rotatable member according to a diametral opposed position and are actuated by the member, the telescoping structure when extended forming
the whirling chamber, the mantel of the latter mentioned member being formed with a cam able to give a number of piercing operations to both piercing devices.
US 8,006,695 describes an inhaler device for inhalation of a medicament from a pierceable capsule comprises a housing for receiving a medicament capsule; closure means for closing the housing, said closure means being moveable relative to the housing; piercing means suitable for piercing a medicament capsule; wherein movement of the closure means relative to the housing causes movement of the piercing means. The invention also provides a holder for a medicament capsule which holder comprises a chamber suitable for receiving a medicament capsule; and means for generating turbulence in a fluid flow through the chamber such that, in use, the turbulent fluid flow causes vibration of a capsule received by the chamber so as to assist in releasing medicament contained within the capsule.
US 7,694,676 describes an inhaler for inhaling powdered pharmaceutical compositions from capsules includes: a lower part; a plate which can be latched to the lower part and with which the lower part can be closed off; a capsule holder for receiving the capsules, this holder being adapted to be lowered into the lower part; a mouthpiece latchable to the plate; a lid which covers the mouthpiece in a closed position and latches it by means of a closure element, the lower part, the plate, the mouthpiece and the lid being hinged together by means of a single joint.
US 8,022,082 discloses an inhaler comprising: a housing containing two windows, a deck in which there are air inlet ports and which is provided with a screen secured by a screen housing, an inhalation chamber connected to the deck on which there is a push button provided with two sharpened pins and movable counter to a spring, a mouthpiece which is connected to the housing, the deck, and a cover via a spindle to enable it to be flipped open or shut, and three holes with diameters below 1 mm in the central region around the capsule chamber and underneath the screen housing and screen.
US 7,252,087 discloses an inhaler utilizing a multi-functional actuating member. Multifunctional actuating member as disclosed in US '087 in a first functional position allows a closure element to be disengaged from a lower part of the housing, and in a second functional position allows a mouthpiece to be pivoted away from the lower part of the housing.
US 7,284,553 discloses a powder inhaler operating on the Bernoulli principle. It discloses an inhaler with a capsule chamber including raised elements on either the inner surface of the capsule chamber or on the outer surface of the capsule. Although the prior art discussed many different kinds of inhalers for the delivery of medicament, a need still remains in the art for design and development of improved inhalers for powdered inhalant delivery based on the factors that influence treatment compliance such as drug to be delivered, ease of handling and patient's preference. The present invention therefore aims at adequately addressing these and other needs existing in the art by improving the known inhalers further in terms of their handling.
The invention is thus concerned with improved inhaling devices with two hinge system intended to disperse the contents of the powdered pharmaceutical composition. In the normal use of the Dry Powder Inhaler; patient opens the lid, then the mouth piece and inserts the capsule containing powdered pharmaceutical composition. Patient then presses the actuating member that leads to piercing of the capsule containing powdered pharmaceutical composition. The piercing elements attached to the actuating member pierce the capsule from one side allowing the powdered pharmaceutical composition contained in the capsule to come out when the patient inhales from the mouthpiece.
The 'two hinge' design in the inhaler of present invention employs two separate hinges. One hinge is for the lid and the mouth piece and second is for the base plate. The patient is required to open the base plate only as and when required. Use of second and distinct hinge
prevents the accidental opening of the base plate, thereby avoiding the contamination of the medicament. Also, the non-protruding actuating member makes handling and storing of the device very convenient. Further, the shape of the inhaler which is round across the top and on one side is configured at an angle in such a way that patient is able to have an appropriate grip on the device and finds it very convenient to actuate the device without losing control over the holding of the device Ob jects of invention
An object of the present invention is to overcome the drawbacks of the prior art.
Another object of the present invention is to provide an inhaler device with two hinge systems (6, 8).
Yet another object of the present invention is to provide an inhaler device with two hinge systems, wherein the mouthpiece (3) and the lid (1) is joined to a single hinge (8).
Yet another object of the present invention is to provide an inhaler device with two hinge systems, wherein the base plate (4) is hinged separately from the mouthpiece and lid to hinge (6).
Yet another object of the present invention is to provide an inhaler utilizing base plate (4) devoid of any holes.
Yet another object of the present invention is to provide an inhaler wherein the gripping aid (9) is disposed distal to the actuating member (5).
Summary of the invention
Accordingly to one aspect of the present invention there is provided an inhaler device comprising: a housing (2), a base plate (4) covering the housing (2), a medicament holder (10) integrated with the base plate (4), a mouthpiece (3) sitting over the base plate (4), a lid (1) which covers the mouthpiece (3), at least one piercing element (11), an actuating member
(5) , a spring (12), and is characterized in that the inhaler device is a two hinge system (6,8) wherein the base plate (4) is joined to hinge (6); the mouthpiece (3) and the lid (1) are joined to the hinge (8). Brief description of the accompanying drawings
Figure 1 illustrates the essential components of the inhaler in accordance with the present invention wherein the housing (2) which accommodates the base plate (4) and is covered by the latter, the mouthpiece (3) with gripping aid (9). The base plate (4) is joined to the hinge
(6) and the mouthpiece (3) and the lid (1) is hinged together distinctly from the base plate to hinge (8). The gripping aid (9) is disposed distal to the actuating member (5).
Figure 2 illustrates the Top view of the medicament holder (10) mounted on the underside of the base plate (4). Figure 3 illustrates the closed view of the mouthpiece (3) sitting over the base plate (4) that is integrated with the medicament holder (10). The two hinges (6, 8) are distinctly marked.
Figure 4 illustrates the radial partial sectional view of the inhaler depicting the lid (1), mouthpiece (3), piercing elements (11), actuating member (5), spring (12), medicament holder (10), inspection windows (7), and the mouthpiece and lid attached to hinge (8).
Figure 5 illustrates the side perspective of the inhaler in a fully closed position.
Figure 6 illustrates the top view of the inhaler base plate (4) devoid of any holes.
Figure 7 illustrates the inhaler with distinct two hinge system (6, 8).
Figure 8 illustrates the graph for square root of the pressure drop versus the flow rate in the present inhaler depicting relatively high resistance to air flow.
Detailed Description of the Invention
The following presents a simplified summary of the invention in order to provide a basic understanding of some aspects of the invention. This summary is not an extensive overview of the present invention. It is not intended to identify the key/critical elements of the invention or to delineate the scope of the invention. Its sole purpose is to present some concept of the invention in a simplified form as a prelude to a more detailed description of the invention presented later.
In accordance with present invention an inhaler for inhaling powdered pharmaceutical compositions is provided from capsules which are inserted in a medication holder provided in the inhaler before use. According to the present invention, after the capsule has been inserted in the medication holder of the device, the patient can press an actuating member which can be moved from a resting position, thereby cooperating with at least one piercing element which can enter into the medication holder. The capsule is pierced by the minimum of one piercing element and the pharmaceutical composition is released.
Other aspects, advantages, and salient features of the invention will become apparent to those skilled in the art from the following detailed description, which, taken in conjunction with the annexed drawings, discloses exemplary embodiments of the invention.
The inhaler according to the present invention as shown in the figures 1, 2, 3 and 4 essentially comprises of a housing (2) which accommodates the base plate (4) and is covered by the latter, the mouthpiece (3) with gripping aid (9); the said base plate (4) is joined to the hinge (6) and the mouthpiece (3) and the lid (1) is hinged together distinctly from the base
plate to hinge (8); The gripping aid (9) is disposed distal to the actuating member (5).Inspectional window (7) further allows to inspect the internal elements of the device. A medicament holder (10) is mounted on the underside of the base plate (4). One or more piercing elements (11) for piercing the capsules are attached from inside of the actuating member (5) and a spring (12) is also configured to link the actuating member; characterized in that the actuator when pressed from outside, the spring element (12) gets compressed and enables the piercing elements (11) to move linearly and pierce the capsule such that the medicament inside the capsule is released and the spring element retracts thereafter. The terms and words used in the following description and claims are not limited to the bibliographical meanings, but, are merely used by the inventor to enable a clear and consistent understanding of the invention.
Lid (1) offers protection to the device components by preventing entry of dust or any other extraneous particles.
Mouthpiece (3) is the component through which the patient inhales the powdered pharmaceutical composition. Base plate (4) ensures that the medicament holder (10) is held securely and always remains aligned to the mouth piece (3) for a smooth flow of the medicament.
Actuating member (5) is responsible for locking & unlocking of the lid (1) and holds the piercing elements (11) in an appropriate position. When the actuating member (5) is moved forward, it ensures appropriate piercing of the capsule in such a way that the powdered pharmaceutical composition is available for inhalation by the patient.
Hinge (6) is responsible for holding the base plate (4) in an appropriate position in such a way that the medicament holder (10) is always aligned to the mouth piece (3).
Inspection window (7) provides a view of the medicament holder (10) and allows the patient to confirm the presence of capsule in the medicament holder (10).
Hinge (8) is responsible for appropriate movement of the lid (1) and mouth piece (3).
Gripping aid (9) on the mouth piece offers a grip for the patient to open the mouth piece so that the capsule containing the powdered pharmaceutical composition could be placed in the medicament holder (10).
In an embodiment of present invention, the inhaler is operated in the following manner. a) The lid (1) is opened by pressing the actuating member (5)
b) The lid (1) is pulled upwards and away from the base to expose the mouthpiece (3)
c) The mouthpiece (3) is opened by pulling the gripping aid (9) located on both sides of the mouthpiece (3).
d) The capsule is placed in the medicament holder (10) of the inhaler of the present invention
e) The mouthpiece (3) is closed firmly. The lid (1) is kept open.
f) The inhaler of the present invention is held in such a position that the mouthpiece (3) is pointed upwards
g) The actuating member (5) is pressed to move the piercing element (11) to pierce the capsules.
h) The powdered pharmaceutical composition is inhaled from the capsule.
The device may be made from any suitable material. Preferably the device is made of plastic, for example ABS (acrylonitrile butadiene styrene), PC (polycarbonate), PA (polyacetal) or PS (polystyrene), or mixtures thereof, or of an antistatic material such as delrin or stainless steel
The inhaler according to the invention allows the pharmaceutical composition to be delivered more reliably compared to the devices known from the prior art.
The advantages of the present inhaler are as follows.
1. The patient is required to open the base plate only as and when required. Use of second and distinct hinge prevents the accidental opening of the base plate, thereby avoiding the contamination of the medicament.
2. Also, the non-protruding actuating member makes handling of the device and storing of the device, very convenient.
3. Further, the shape of the inhaler which is round across the top and on one side, is configured at an angle in such a way that patient is able to have an appropriate grip on the device and finds it very convenient to actuate the device without losing control over the holding of the device
An inhaler device with two hinge system utilizing a base plate devoid of any holes was measured to have a flow resistance of about 0.07 /L, mm \ resulting in a flow rate of about 40 L min"1 with a pressure drop of about 4 kPa across the inhaler.
The flow resistance can be calculated using the formulae: R = P0'5 / Q where Q is the flow rate (L/min), P is the pressure drop (kPa) across the inhaler and R is the flow resistance [kPa0'5/ (L/min)] .
In the system, the inhalation pressure drops of between 2 kpa and 6 kpa produced resultant flow rates of about between 25 and 55 liters per minute.
The present invention relates to the use of an inhaler device as described above for the administration of powdered pharmaceutical composition that is suitable for the treatment of asthma or chronic obstructive pulmonary disease by inhalation.
The pressure drop versus flow rate curve depends upon the construction of the inhaler.
The inhaler in accordance with the present invention was tested to measure its resistance to flow which is an important characteristic of inhalers.
According to the Bernoulli principle, when the square root of the pressure drop is plotted versus the flow rate, the resistance of the inhaler is the slope of the linear portion of the curve. An exemplary graph can be seen in Fig 8 for an inhaler device in accordance with the present invention. The graph depicted in Fig 8 indicates relatively high resistance to air flow, the curve increasing rapidly with the flow rate. The inhaler according to the present invention may include design features provided by the recognition that different powdered drugs have different characteristics. Thus, for increased delivery efficiency, the flow parameters of the inhaler should advantageously be adjusted for the specific drug being delivered. These adjustments can be made by adjusting the air flow. The air flow can be controlled by drilling additional air supply hole or by increasing and decreasing the size of the opening of the air supply hole.
Preferably, the powdered pharmaceutical composition contained within the capsule is a dry powder medicament. The term capsule is intended to be understood broadly and includes any suitable receptacle for powdered pharmaceutical compositions. The capsule may be formed from any suitable material, including gelatin, HPMC, or plastic.
In an embodiment the invention provides pharmaceutical composition which includes powdered pharmaceuticals can be administered by inhalation. Particularly preferred in this context are pharmaceutical compositions selected from among the anticholinergics, beta-2- agonists, steroids, PDE IV-inhibitors, LTD4-antagonists and EGFR-kinase inhibitors.
Anticholinergics for use are preferably selected from among TIOTROPIUM bromide, oxitropium bromide, flutropium bromide, ipratropium bromide, glycopyrronium salts, trospium chloride, tolterodine, tropenol 2,2-diphenylpropionate methobromide, scopine 2,2-
diphenylpropionate methobromide, scopine 2-fluoro-2,2-diphenylacetate methobromide, tropenol 2-fluoro-2,2-diphenylacetate methobromide, tropenol 3,3',4,4'-tetrafluorobenzilate methobromide, scopine 3,3',4,4'-tetrafluorobenzilate methobromide, tropenol 4,4'- difluorobenzilate methobromide, scopine 4,4'-difluorobenzilate methobromide, tropenol 3,3'- difluorobenzilate methobromide, scopine 3,3'-difluorobenzilate methobromide, tropenol 9- hydroxy-fluorene-9-carboxylate methobromide, tropenol 9-fluoro-fluorene-9-carboxylate methobromide, scopine 9-hydroxy-fluorene-9-carboxylate methobromide, scopine 9-fluoro- fluorene-9-carboxylate methobromide, tropenol 9-methyl-fluorene-9-carboxylate methobromide, scopine 9-methyl-fluorene-9-carboxylate methobromide, cyclopropyltropine benzilate methobromide, 2,2-diphenylpropionate cyclopropyltropine methobromide, cyclopropyltropine 9-hydroxy-xanthene-9-carboxylate methobromide, cyclopropyltropine 9- methyl-fluorene-9-carboxylate methobromide, cyclopropyltropine 9-methyl-xanthene-9- carboxylate methobromide, cyclopropyltropine 9-hydroxy-fluorene-9-carboxylate methobromide, methyl 4,4'-difluorobenzilate cyclopropyltropine methobromide, tropenol 9- hydroxy-xanthene-9-carboxylate methobromide, scopine 9-hydroxy-xanthene-9-carboxylate methobromide, tropenol 9-methyl-xanthene-9-carboxylate methobromide, scopine 9-methyl- xanthene-9-carboxylate methobromide, tropenol 9-ethyl-xanthene-9-carboxylate methobromide, tropenol 9-difluoromethyl-xanthene-9-carboxylate methobromide and scopine 9-hydroxymethyl-xanthene-9-carboxylate methobromide, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the solvates and/or hydrates thereof.
Beta-2-agonists used are preferably selected from among albuterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, salmeterol, salmefamol, soterenot, sulphonterol, tiaramide, terbutaline, tolubuterol, CHF-1035, HOKU-81, KUL-1248, 3-(4-{6- [2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-hexyl- oxy}-butyl)- benzenesulphonamide, 5-[2-(5,6-diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-lH-
quinolin- -2-one, 4-hydroxy-7- [2- { [2- { [3 -(2-phenylethoxy)propyl] sulphonyl} ethyl] -ami- no}ethyl]-2(3H)-benzothiazolone, l-(2-fluoro-4-hydroxyphenyl)-2-[4-(l-benzimidazolyl)-2- methyl-2-butylamin- o]ethanol, l-[3-(4-methoxybenzyl-amino)-4-hydroxyphenyl]-2-[4-(l- benzimida- zolyl)-2-methyl-2-butylamino]ethanol, l-[2H-5-hydroxy-3-oxo-4H-l,4- benzoxazin-8-yl]-2-[3-(4-N,N-dimethylaminoph- enyl)-2-methyl-2-propylamino]ethanol, 1- [2H-5-hydroxy-3-oxo-4H-l,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-me- thyl-2- propylamino]ethanol, l-[2H-5-hydroxy-3-oxo-4H-l,4-benzoxazin-8-yl]-2-[3-(4-n- butyloxyphenyl)-2- -methyl-2-propylamino]ethanol, 1 -[2H-5-hydroxy-3-oxo-4H- 1 ,4- benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-l- ,2,4-triazol-3-yl]-2-methyl-2- butylaminojethanol, 5-hydroxy-8-(l-hydroxy-2-isopropylaminobutyl)-2H-l,4-benzoxazin-3- (4H)-on- e, l-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butylamino)ethanol and 1- (4-ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert.-butylamino)- ethanol, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of ihrer pharmacologically acceptable acid addition salts, solvates and/or hydrates thereof.
The steroids used are preferably selected from among prednisolone, prednisone, butixocortpropionate, RPR-106541, flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, ST- 126, dexamethasone, (S)- fluoromethyl6.quadrature.,9.quadrature.-difluoro-17.quadrature.-[(2-f- uranylcarbonyl)oxy]- 1 l.quadrature.-hydroxy-16.quadrature.-methyl-3-oxo-and- rosta-l,4-diene-17.quadrature.- carbothionate, (S)-(2-oxo-tetrahydro-furan-3S-yl) 6.quadrature.,9.quadrature.-difluoro- 11. quadrature. -hydroxy- 16.quadrature- .-methyl-3-oxo-17.quadrature.-propionyloxy- androsta-l,4-diene-17.quadratur- e.-carbothionate and etiprednol-dichloroacetate (BNP-166), optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the salts and derivatives thereof, the solvates and/or hydrates thereof.
PDE IV inhibitors used are preferably selected from among enprofyllin, theophyllin, roflumilast, ariflo (cilomilast), CP-325,366, BY343, D-4396 (Sch-351591), AWD-12-281 (GW-842470), N-(3,5-dichloro-l-oxo-pyridin-4-yl)-4-difluoromethoxy-3-
cyclopropylmethox- ybenzamide, NCS-613, pumafentine, (-)p-[(4aR*,10bS*)-9-ethoxy- 1,2,3, 4,4a, 10b-hexahydro-8-methoxy-2-methylbe- nzo[s][l,6]naphthyridin-6-yl]-N,N- diisopropylbenzamide, (R)-(+)-l-(4-bromobenzyl)-4-[(3-cyclopentyloxy)-4-methoxyphenyl]- 2-pyrrol- idone, 3-(cyclopentyloxy-4-methoxyphenyl)-l-(4-N'-[N-2-cyano-S-methyl-isot- hioureido]benzyl)-2-pyrrolidone, cis[4-cyano-4-(3-cyclopentyloxy-4- methoxyphenyl)cyclohexane- 1 -carboxylic acid] , 2-carbomethoxy-4-cyano-4-(3- cyclopropylmethoxy-4-difluoromethoxyph- enyl)cyclohexan- 1 -one, cis[4-cyano-4-(3- cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-l— ol], (R)-(+)-ethyl[4-(3- cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-yliden- e]acetate, (S)-(-)-ethyl[4-(3- cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2— ylidene]acetate, CDP840, Bay- 198004, D- 4418, PD-168787, T-440, T-2585, arofyllin, atizoram, V-11294A, CI-1018, CDC-801, CDC- 3052, D-22888, YM-58997, Z-15370, 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9H- pyrazolo[3,4-c]-l,2,4— triazolo[4,3-a]pyridine and 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(tert- butyl)-9H-pyrazolo[3,4-c]-l,2,4- -triazolo[4,3-a]pyridine, optionally in the form of the racemates, enantiomers or diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts thereof, solvates and/or hydrates thereof.
LTD4-antagonists used are preferably selected from among montelukast, l-(((R)-(3-(2-(6,7- difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2-(2-hydroxy— 2- propyl)phenyl)thio)methylcyclopropane-acetic acid, l-(((l(R)-3(3-(2-(2,3- dichlorothieno[3,2-b]pyridin-5-yl)-(E)-ethenyl)phen- yl)-3-(2-(l -hydroxy- 1- methylethyl)phenyl)propyl)thio)methyl)cyclopropanace- tic acid, pranlukast, zafirlukast, [2- [[2-(4-tert-butyl-2-thiazolyl)-5-benzofuranyl]oxymethyl]phenyl]acetic acid, MCC-847 (ZD- 3523), MN-001, MEN-91507 (LM-1507), VUF-5078, VUF-K-8707 and L-733321, optionally in the form of the racemates, enantiomers or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts thereof as well as optionally in the form of the salts and derivatives thereof, the solvates and/or hydrates thereof.
EGFR-kinase inhibitors used are preferably selected from among cetuximab, trastuzumab, ABX-EGF, Mab ICR-62, 4-[(3-chloro-4-fluorophenyl)amino]-6-{ [4-(morpholin-4-yl)-l-oxo- 2-buten- 1 - -yl] amino } -7-cyclopropylmethoxy-quinazoline, 4- [(R)-( 1 -phenyl-ethyl)amino] -6- { [4-(morpholin-4-yl)-l-oxo-2-buten-l-yl]— amino }-7-cyclopentyloxy-quinazoline, 4-[(3- chloro-4-fluoro-phenyl)amino]-6-{ [4-((R)-6-methyl-2-oxo-morpholin-4- -yl)-l-oxo-2-buten-
1- yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoli- ne, 4-[(3-chloro-4-fluoro- phenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpholin- -4-yl)-ethoxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-am- ino]-l-oxo-
2- buten- 1 -yl } amino)-7-cyclopropylmethoxy-quinazoline, 4- [(R)-( 1 -phenyl-ethyl)amino] -6- ( { 4- [N-(tetrahydropyran-4-yl)-N-methyl-am- ino] - 1 -oxo-2-buten- 1 -yl } amino)-7- cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy- ethyl)-N-methyl-am- ino] - 1 -oxo-2-buten- 1 -yl } amino)-7-cyclopentyloxy-quinazoline, 4- [(3- chloro-4-fluorophenyl)amino] -6- { [4-(N,N-dimethylamino)- 1 -oxo-2-bute- n- 1 -yl] amino } -7- [(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6,7-bis-(2- methoxy-ethoxy)-quinazoline, 4- [(R)-( 1 -phenyl-ethyl)amino] -6-(4-hydroxy-phenyl)-7H- pyrrolo[2,3-d]pyrim- idine, 3-cyano-4-[(3-chloro-4-fluorophenyl)amino]-6-{ [4-(N,N- dimethylamino- )- 1 -oxo-2-buten- 1 -yl] amino } -7-ethoxy-quinoline, 4- [(R)-( 1 -phenyl- ethyl)amino] -6- { [4-((R)-6-methyl-2-oxo-morpholin-4-yl)- 1 - -oxo-2-buten- 1 -yl] amino } -7- methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{ [4-(morpholin-4-yl)-l-oxo-2- buten-1- -yl]amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-ethynyl- phenyl)amino]-6-{ [4-(5,5-dimethyl-2-oxo-morpholin-4-yl)-l-o- xo-2-buten- 1 -yl] amino }- quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{2-[4-(2-oxo-morpholin-4-yl)-piperi- din-l-yl]-ethoxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4- amino-cyclohexan-l-yloxy)— 7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]- 6-(trans-4-methanesulphonylamino-cycl- ohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3- chloro-4-fluoro-phenyl)amino]-6-(tetrahydropyran-3-yloxy)-7-methoxy- -quinazoline, 4-[(3- chloro-4-fluoro-phenyl)amino] -6- { 1 - [(morpholin-4-yl)carbonyl] -piper- idin-4-yloxy } -7- methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(piperidin-3-yloxy)-7- methoxy-quina- zoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[l-(2-acetylamino-ethyl)-pip-
eridin-4-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6- (tetrahydropyran-4-yloxy)-7-ethoxy— quinazoline, 4-[(3-cmoro-4-fluoro-phenyl)amino]-6- {trans-4-[(morpholin-4-yl)carbonyla- mino]-cyclohexan-l-yloxy}-7-methoxy-quinazoline, 4- [(3-chloro-4-fluoro-phenyl)amino] -6- { 1 - [(piperidin- 1 -yl)carbonyl] -piper- idin-4-yloxy } -7- methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(cis-4-{N— [(morpholin-4- yl)carbony- l]-N-methyl-amino}-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro- 4-fluoro-phenyl)amino]-6-(trans-4-ethansulphonylamino-cycloh- exan-l-yloxy)-7-methoxy- quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(l-methanesulphonyl-piperidin-4-ylo- xy)-7-(2-methoxy-ethoxy)-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[l-(2- methoxy-acetyl)-piperidin-4-y- loxy]-7-(2-methoxy-ethoxy)-quinazoline, 4-[(3-ethynyl- phenyl)amino]-6-(tetrahydropyran-4-yloxy]-7-methoxy-quinazo- line, 4-[(3-chloro-4-fluoro- phenyl)amino] -6-(cis-4- { N- [(piperidin- 1 -yl)car- bonyl] -N-methyl-amino } -cyclohexan- 1 - yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{cis-4-[(morpholin-4- yl)carbonylami- no]-cyclohexan-l-yloxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro- phenyl)amino]-6-{ l-[2-(2-oxopyrrolidin-l-yl)ethyl]— piperidin-4-yloxy}-7-methoxy- quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-(l-acetyl-piperidin-4-yloxy)-7-methoxy-quin- azoline, 4-[(3-ethynyl-phenyl)amino]-6-(l-methyl-piperidin-4-yloxy)-7-meth- oxy- quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-(l-methanesulphonyl-piperidin-4-yloxy)-7-me- thoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(l-methyl-piperidin-4-yloxy)-7(2- me- thoxy-ethoxy)-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6-{ l-[(morpholin-4- yl)carbonyl]-piperidin-4-y- loxy}-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro- phenyl)amino]-6-{ l-[(N-methyl-N-2-methoxyethyl-amin- o)carbonyl]-piperidin-4-yloxy}-7- methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(l-ethyl-piperidin-4-yloxy)-7- metho- xy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-methanesulphonyl- N-methyl- -amino)-cyclohexan-l-yloxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro- phenyl)amino]-6-[cis-4-(N-acetyl-N-methyl-amino)-cy- clohexan-l-yloxy]-7-methoxy- quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methylamino-cyclohexan-l-y- loxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[trans-4-(N- methanesulphonyl-N-meth- yl-amino)-cyclohexan-l-yloxy]-7-methoxy-quinazoline, 4-[(3-
chloro-4-fluoro-phenyl)amino]-6-(trans-4-dimethylamino-cyclohexan-l- -yloxy)-7-methoxy- quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-{N-[(morpholin-4-yl)carbon- yl]-N-methyl-amino}-cyclohexan-l-yloxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro- phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4— yl)-ethoxy]-7-[(S)-(tetrahydrofuran- 2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(l-methanesulphonyl- piperidin-4-ylo- xy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(l- cyano-piperidin-4-yloxy)-7-metho- xy-quinazoline, and 4-[(3-chloro-4-fluoro- phenyl)amino]-6-{ l-[(2-methoxyethyl)carbonyl] -piper- idin-4-yloxy}-7-methoxy- quinazoline, optionally in the form of the racemates, enantiomers or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts thereof, the solvates and/or hydrates thereof.
Examples of acid addition salts with pharmacologically acceptable acids which the compounds may be capable of forming include salts selected from among the hydrochloride, hydrobromide, hydroiodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrobenzoate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate, preferably hydrochloride, hydrobromide, hydrosulphate, hydrophosphate, hydrofumarate and hydromethanesulphonate.
The powdered pharmaceutical compositions may contain the above-mentioned active substances as well as the salts, esters thereof, or combinations of these active substances, salts and esters. Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention.
Claims
1. An inhaler device comprising:
- a housing (2),
-a base plate (4) covering the housing (2),
- a medicament holder (10) integrated with the base plate (4),
- a mouthpiece (3) sitting over the base plate (4),
- a lid (1) which covers the mouthpiece (3),
- at least one piercing element (11),
- an actuating member (5),
- a spring (12),
and is characterized in that the inhaler device is a two hinge system (6,8) wherein
- the base plate (4) is joined to hinge (6);
- the mouthpiece (3) and the lid (1) are joined to the hinge (8).
2. An inhaler device according to claim 1, wherein the base plate (4) is hinged separately from the mouthpiece (3) and lid (1).
3. An inhaler device according to claim 1, wherein the piercing elements (11) are attached from inside of the actuating member (5).
4. An inhaler device according to claim 1, wherein the spring (12) is configured to link the actuating member (5).
5. An inhaler device according to claim 4, wherein in order to assist piercing, the actuating member (5) when pressed causes the spring element (12) to get compressed which enables the piercing elements ( 11 ) to move linearly.
6. An inhaler device according to claim 1, wherein the device further comprises a gripping aid (9) on the mouthpiece (3) which offers a grip to open the mouthpiece (3).
7. An inhaler device according to claim 1, wherein the device further comprises an inspection window (7) to see across the inhaler device.
8. An inhaler device according to claim 6, wherein the gripping aid (9) is disposed distal to the actuating member (5).
9. An inhaler device according to claim 1, wherein the medicament holder (10) is mounted on the underside of the base plate (4).
10. An inhaler device according to claim 1, wherein the base plate is devoid of any holes.
11. An inhaler device according to claim 1, wherein the medicament holder (10) is designed to contain a capsule with powdered pharmaceutical composition.
12. An inhaler device according to claim 11, wherein the powdered pharmaceutical composition is suitable for the treatment of asthma or chronic obstructive pulmonary disease by inhalation.
13. An inhaler device according to claim 11, wherein the powdered pharmaceutical composition contained within the capsule is a dry powder medicament.
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2016011003A MX2016011003A (en) | 2014-02-25 | 2015-02-23 | Inhaler. |
| EP15711296.2A EP3110483B1 (en) | 2014-02-25 | 2015-02-23 | Inhaler |
| BR112016019649-0A BR112016019649B1 (en) | 2014-02-25 | 2015-02-23 | INHALATION DEVICE |
| US15/121,430 US10556069B2 (en) | 2014-02-25 | 2015-02-23 | Inhaler |
| UAA201609743A UA117517C2 (en) | 2014-02-25 | 2015-02-23 | Inhaler |
| PL15711296T PL3110483T3 (en) | 2014-02-25 | 2015-02-23 | Inhaler |
| CA2939310A CA2939310C (en) | 2014-02-25 | 2015-02-23 | Inhaler |
| JP2016554637A JP6509894B2 (en) | 2014-02-25 | 2015-02-23 | Inhaler |
| CN201580010117.0A CN106029140B (en) | 2014-02-25 | 2015-02-23 | Inhalator |
| AU2015221812A AU2015221812B2 (en) | 2014-02-25 | 2015-02-23 | Inhaler |
| ES15711296T ES2714566T3 (en) | 2014-02-25 | 2015-02-23 | Inhaler |
| RU2016137683A RU2655131C2 (en) | 2014-02-25 | 2015-02-23 | Inhaler |
| PH12016501659A PH12016501659B1 (en) | 2014-02-25 | 2016-08-19 | Inhaler |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN663/MUM/2014 | 2014-02-25 | ||
| IN663MU2014 IN2014MU00663A (en) | 2014-02-25 | 2015-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015128789A1 true WO2015128789A1 (en) | 2015-09-03 |
Family
ID=52697485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2015/051350 WO2015128789A1 (en) | 2014-02-25 | 2015-02-23 | Inhaler |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10556069B2 (en) |
| EP (1) | EP3110483B1 (en) |
| JP (1) | JP6509894B2 (en) |
| CN (1) | CN106029140B (en) |
| AU (1) | AU2015221812B2 (en) |
| BR (1) | BR112016019649B1 (en) |
| CA (1) | CA2939310C (en) |
| ES (1) | ES2714566T3 (en) |
| HU (1) | HUE042087T2 (en) |
| IN (1) | IN2014MU00663A (en) |
| MX (1) | MX2016011003A (en) |
| MY (1) | MY180735A (en) |
| PH (1) | PH12016501659B1 (en) |
| PL (1) | PL3110483T3 (en) |
| PT (1) | PT3110483T (en) |
| RU (1) | RU2655131C2 (en) |
| UA (1) | UA117517C2 (en) |
| WO (1) | WO2015128789A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202017102334U1 (en) | 2016-08-25 | 2017-11-29 | Alfred Von Schuckmann | Device for inhaling powdery substances |
| US20190076607A1 (en) * | 2017-09-13 | 2019-03-14 | Lupin Atlantis Holdings Sa | Inhaler and mesh for an inhaler |
| USD983354S1 (en) | 2020-12-21 | 2023-04-11 | Rpc Formatec Gmbh | Inhaler |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA173518S (en) | 2016-02-08 | 2017-09-01 | Nicoventures Holdings Ltd | Cartridge for an electronic cigarette |
| GB201605105D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Vapour provision apparatus |
| GB201605102D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Mechanical connector for electronic vapour provision system |
| GB201605101D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Electronic vapour provision system |
| GB201605100D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Vapour provision system |
| EP3487776A1 (en) | 2016-07-22 | 2019-05-29 | Nicoventures Holdings Limited | Case for a vapour provision device |
| USD831190S1 (en) * | 2016-11-08 | 2018-10-16 | Alfred Von Schuckmann | Inhaler |
| USD849927S1 (en) * | 2017-08-17 | 2019-05-28 | Alfred Von Schuckmann | Inhaler |
| PL234586B1 (en) * | 2017-08-31 | 2020-03-31 | Pulinno Spolka Z Ograniczona Odpowiedzialnoscia | Inhaler of a single dose of dry powder |
| JP7110336B2 (en) * | 2017-10-24 | 2022-08-01 | マーキシン リミテッド | inhaler |
| AU201815816S (en) * | 2018-04-04 | 2018-10-30 | Chia Tai Tianqing Pharmaceutical Group Co | Inhaler |
| USD1010101S1 (en) | 2020-09-18 | 2024-01-02 | Trudell Medical International | Holding chamber |
| CN113813479B (en) * | 2021-08-19 | 2023-12-01 | 丰都县中医院 | Self-administration tiotropium bromide powder applicator for reserved asthma patient |
| CN113926031B (en) * | 2021-11-16 | 2023-08-15 | 南京茂升德科技有限公司 | Medicinal tiotropium bromide powder feeding device for asthmatic patient |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3807400A (en) | 1971-07-17 | 1974-04-30 | Isf Spa | Inhaling device for medicinal powder compositions |
| US20060237016A1 (en) * | 2005-04-22 | 2006-10-26 | Boehringer Ingelheim International Gmbh | Dry powder inhaler |
| US7252087B2 (en) | 2003-11-08 | 2007-08-07 | Boehringer Ingelheim International Gmbh | Powder inhaler |
| US7284553B2 (en) | 2002-12-12 | 2007-10-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder inhaler comprising a chamber for a capsule for taking up a non-returnable capsule being filled with an active ingredient |
| US8006695B2 (en) | 2004-11-10 | 2011-08-30 | Cipla Limited | Inhaler |
| US8022082B2 (en) | 2002-04-09 | 2011-09-20 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Method for the administration of an anticholinergic by inhalation |
| WO2012047182A2 (en) * | 2010-10-07 | 2012-04-12 | Mahmut Bilgic | Single dose dry powder inhalation device |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4948534B2 (en) * | 2006-06-27 | 2012-06-06 | 大塚製薬株式会社 | Powder inhaler |
| CN2915141Y (en) * | 2006-07-06 | 2007-06-27 | 福建精致模具有限公司 | A capsule type dry powder inhaler |
| DE102006045788A1 (en) * | 2006-09-26 | 2008-03-27 | Alfred Von Schuckmann | Dispenser for powdery masses |
| US20130047985A1 (en) * | 2010-04-23 | 2013-02-28 | 3M Innovative Properties Company | Dry powder inhaler assembly and containers |
| US9849255B2 (en) * | 2011-11-25 | 2017-12-26 | Mahmut Bilgic | Inhalation device |
| DE102012103482A1 (en) * | 2012-04-20 | 2013-10-24 | Alfred Von Schuckmann | Device for inhaling powdery substances |
| ZA201408393B (en) * | 2013-11-19 | 2015-11-25 | Cipla Ltd | Inhaler device |
-
2015
- 2015-02-23 PL PL15711296T patent/PL3110483T3/en unknown
- 2015-02-23 US US15/121,430 patent/US10556069B2/en active Active
- 2015-02-23 MX MX2016011003A patent/MX2016011003A/en active IP Right Grant
- 2015-02-23 BR BR112016019649-0A patent/BR112016019649B1/en active IP Right Grant
- 2015-02-23 RU RU2016137683A patent/RU2655131C2/en active
- 2015-02-23 IN IN663MU2014 patent/IN2014MU00663A/en unknown
- 2015-02-23 CA CA2939310A patent/CA2939310C/en active Active
- 2015-02-23 CN CN201580010117.0A patent/CN106029140B/en active Active
- 2015-02-23 UA UAA201609743A patent/UA117517C2/en unknown
- 2015-02-23 AU AU2015221812A patent/AU2015221812B2/en active Active
- 2015-02-23 PT PT15711296T patent/PT3110483T/en unknown
- 2015-02-23 JP JP2016554637A patent/JP6509894B2/en active Active
- 2015-02-23 EP EP15711296.2A patent/EP3110483B1/en active Active
- 2015-02-23 HU HUE15711296A patent/HUE042087T2/en unknown
- 2015-02-23 ES ES15711296T patent/ES2714566T3/en active Active
- 2015-02-23 WO PCT/IB2015/051350 patent/WO2015128789A1/en active Application Filing
- 2015-02-23 MY MYPI2016702930A patent/MY180735A/en unknown
-
2016
- 2016-08-19 PH PH12016501659A patent/PH12016501659B1/en unknown
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3807400A (en) | 1971-07-17 | 1974-04-30 | Isf Spa | Inhaling device for medicinal powder compositions |
| US8022082B2 (en) | 2002-04-09 | 2011-09-20 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Method for the administration of an anticholinergic by inhalation |
| US7284553B2 (en) | 2002-12-12 | 2007-10-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder inhaler comprising a chamber for a capsule for taking up a non-returnable capsule being filled with an active ingredient |
| US7252087B2 (en) | 2003-11-08 | 2007-08-07 | Boehringer Ingelheim International Gmbh | Powder inhaler |
| US8006695B2 (en) | 2004-11-10 | 2011-08-30 | Cipla Limited | Inhaler |
| US20060237016A1 (en) * | 2005-04-22 | 2006-10-26 | Boehringer Ingelheim International Gmbh | Dry powder inhaler |
| US7694676B2 (en) | 2005-04-22 | 2010-04-13 | Boehringer Ingelheim Gmbh | Dry powder inhaler |
| WO2012047182A2 (en) * | 2010-10-07 | 2012-04-12 | Mahmut Bilgic | Single dose dry powder inhalation device |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202017102334U1 (en) | 2016-08-25 | 2017-11-29 | Alfred Von Schuckmann | Device for inhaling powdery substances |
| WO2018036836A1 (en) | 2016-08-25 | 2018-03-01 | Alfred Von Schuckmann | Device for inhaling powdery substances |
| CN109641117A (en) * | 2016-08-25 | 2019-04-16 | 艾尔弗雷德.冯舒克曼 | Device for inhalation of dust shape substance |
| CN109641117B (en) * | 2016-08-25 | 2022-04-05 | 艾尔弗雷德.冯舒克曼 | Device for inhaling powdery substances |
| US11766529B2 (en) | 2016-08-25 | 2023-09-26 | Alfred Von Schuckmann | Device for inhaling powdery substances |
| US20190076607A1 (en) * | 2017-09-13 | 2019-03-14 | Lupin Atlantis Holdings Sa | Inhaler and mesh for an inhaler |
| WO2019053085A1 (en) | 2017-09-13 | 2019-03-21 | Lupin Atlantis Holdings Sa | Inhaler and mesh for an inhaler |
| CN111315432A (en) * | 2017-09-13 | 2020-06-19 | 鲁品亚特兰蒂斯控股股份公司 | Inhaler and grid for an inhaler |
| CN111315432B (en) * | 2017-09-13 | 2022-09-20 | 鲁品亚特兰蒂斯控股股份公司 | Inhaler and grid for an inhaler |
| USD983354S1 (en) | 2020-12-21 | 2023-04-11 | Rpc Formatec Gmbh | Inhaler |
Also Published As
| Publication number | Publication date |
|---|---|
| US20160375207A1 (en) | 2016-12-29 |
| JP6509894B2 (en) | 2019-05-08 |
| CN106029140A (en) | 2016-10-12 |
| RU2016137683A3 (en) | 2018-03-29 |
| BR112016019649A2 (en) | 2017-08-15 |
| CA2939310C (en) | 2022-05-31 |
| MX2016011003A (en) | 2016-11-30 |
| PH12016501659A1 (en) | 2016-10-03 |
| RU2655131C2 (en) | 2018-05-23 |
| AU2015221812B2 (en) | 2019-12-19 |
| EP3110483B1 (en) | 2018-12-19 |
| PT3110483T (en) | 2019-03-21 |
| ES2714566T3 (en) | 2019-05-29 |
| CA2939310A1 (en) | 2015-09-03 |
| RU2016137683A (en) | 2018-03-29 |
| PL3110483T3 (en) | 2019-06-28 |
| UA117517C2 (en) | 2018-08-10 |
| EP3110483A1 (en) | 2017-01-04 |
| HUE042087T2 (en) | 2019-06-28 |
| CN106029140B (en) | 2019-07-05 |
| US10556069B2 (en) | 2020-02-11 |
| IN2014MU00663A (en) | 2015-09-25 |
| JP2017510343A (en) | 2017-04-13 |
| BR112016019649B1 (en) | 2021-12-07 |
| AU2015221812A1 (en) | 2016-09-08 |
| PH12016501659B1 (en) | 2016-10-03 |
| MY180735A (en) | 2020-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3110483B1 (en) | Inhaler | |
| US7694676B2 (en) | Dry powder inhaler | |
| US9687617B2 (en) | Nebulizer | |
| US7950388B2 (en) | Nebuliser and container | |
| DE102006016903A1 (en) | inhaler | |
| DE102006017699A1 (en) | inhaler | |
| BRPI0614852B1 (en) | SPRAY | |
| CA2505366C (en) | Dry powder inhaler | |
| US8919341B2 (en) | Inhaler | |
| JP2012510324A5 (en) | ||
| JP4825455B2 (en) | Powder inhaler | |
| BRPI0501592B1 (en) | dust inhaler | |
| KR20060114965A (en) | Powder inhaler | |
| MXPA05004558A (en) | Dry powder inhaler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15711296 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2939310 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: IDP00201605397 Country of ref document: ID |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12016501659 Country of ref document: PH |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/011003 Country of ref document: MX |
|
| ENP | Entry into the national phase |
Ref document number: 2016554637 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 15121430 Country of ref document: US |
|
| ENP | Entry into the national phase |
Ref document number: 2015221812 Country of ref document: AU Date of ref document: 20150223 Kind code of ref document: A |
|
| REEP | Request for entry into the european phase |
Ref document number: 2015711296 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: A201609743 Country of ref document: UA Ref document number: 2015711296 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2016137683 Country of ref document: RU Kind code of ref document: A |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016019649 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 112016019649 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160825 |